Rohini Sharma1, Kumar G Kallur2, Jin S Ryu3, Ramanathapuram V Parameswaran4, Henrik Lindman5, Norbert Avril6, Fergus V Gleeson7, Jong D Lee8, Kyung-Han Lee9, Michael J O'Doherty10, Ashley M Groves11, Matthew P Miller12, Edward J Somer12, Charles R Coombes13, Eric O Aboagye14. 1. Department of Experimental Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom. 2. PETCT and Cyclotron Department, HCG, Bangalore, India. 3. Department of Nuclear Medicine, Asan Medical Center, Seoul, South Korea. 4. Department of Nuclear Medicine and PET-CT Division, Manipal Hospital, Bangalore, India. 5. Uppsala University Hospital, Department of Oncology, Uppsala, Sweden. 6. Department of Nuclear Medicine, Barts Health, Queen Mary University of London, London, United Kingdom. 7. Department of Radiology, Churchill Hospital, Oxford Radcliffe Hospitals Trust, Oxford, United Kingdom. 8. Department of Nuclear Medicine, Yonsei University Health System, Seoul, Korea. 9. Department of Nuclear Medicine, Samsung Medical Center, Seoul, Korea. 10. PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom. 11. Institute of Nuclear Medicine, University College London, London, United Kingdom. 12. GE Healthcare Life Sciences, Imaging R&D, Amersham, United Kingdom; and. 13. Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom. 14. Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom eric.aboagye@imperial.ac.uk.
Abstract
UNLABELLED: Integrins are upregulated on both tumor cells and associated vasculature, where they play an important role in angiogenesis and metastasis. Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity for αvβ3/αvβ5 integrin, which can be radiolabeled for PET imaging of angiogenesis. Thus, (18)F-fluciclatide is a potential biomarker of therapeutic response to antiangiogenic inhibitors. The aim of this study was to evaluate the reproducibility of (18)F-fluciclatide in multiple solid-tumor types. METHODS: Thirty-nine patients underwent PET/CT scanning at 40, 65, and 90 min after injection of (18)F-fluciclatide (maximum, 370 MBq) on 2 separate days (2-9 d apart). Patients did not receive any therapy between PET/CT scans. (18)F-fluciclatide images were reported and quantitative measures of uptake were extracted using the PERCIST methodology. Intrasubject reproducibility of PET uptake in all measurable lesions was evaluated by calculating relative differences in SUV between PET scans for each lesion during the 2 imaging sessions. RESULTS: Thirty-nine measurable lesions were detected in 26 patients. Lesion uptake correlated strongly across imaging sessions (r = 0.92, P < 0.05, at 40 min; r = 0.94, P < 0.05, at 65 min; r = 0.94, P < 0.05, at 90 min) with a mean relative difference and SD of the relative difference of 0.006 ± 0.18 at 40 min, 0.003 ± 0.19 at 65 min, and 0.025 ± 0.20 at 90 min. This reflects 95% limits of repeatability of 35%-39% for the difference between the 2 SUV measurements or a variability of 18%-20% in agreement from that observed in well-calibrated multicenter (18)F-FDG studies. CONCLUSION: The test-retest reproducibility of (18)F-fluciclatide across multiple tumor types has been measured and shown to be acceptable. This is an important step in the development of this in vivo biomarker to identify and quantify response to antiangiogenic therapy in cancer patients.
UNLABELLED: Integrins are upregulated on both tumor cells and associated vasculature, where they play an important role in angiogenesis and metastasis. Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity for αvβ3/αvβ5 integrin, which can be radiolabeled for PET imaging of angiogenesis. Thus, (18)F-fluciclatide is a potential biomarker of therapeutic response to antiangiogenic inhibitors. The aim of this study was to evaluate the reproducibility of (18)F-fluciclatide in multiple solid-tumor types. METHODS: Thirty-nine patients underwent PET/CT scanning at 40, 65, and 90 min after injection of (18)F-fluciclatide (maximum, 370 MBq) on 2 separate days (2-9 d apart). Patients did not receive any therapy between PET/CT scans. (18)F-fluciclatide images were reported and quantitative measures of uptake were extracted using the PERCIST methodology. Intrasubject reproducibility of PET uptake in all measurable lesions was evaluated by calculating relative differences in SUV between PET scans for each lesion during the 2 imaging sessions. RESULTS: Thirty-nine measurable lesions were detected in 26 patients. Lesion uptake correlated strongly across imaging sessions (r = 0.92, P < 0.05, at 40 min; r = 0.94, P < 0.05, at 65 min; r = 0.94, P < 0.05, at 90 min) with a mean relative difference and SD of the relative difference of 0.006 ± 0.18 at 40 min, 0.003 ± 0.19 at 65 min, and 0.025 ± 0.20 at 90 min. This reflects 95% limits of repeatability of 35%-39% for the difference between the 2 SUV measurements or a variability of 18%-20% in agreement from that observed in well-calibrated multicenter (18)F-FDG studies. CONCLUSION: The test-retest reproducibility of (18)F-fluciclatide across multiple tumor types has been measured and shown to be acceptable. This is an important step in the development of this in vivo biomarker to identify and quantify response to antiangiogenic therapy in cancer patients.
Authors: Babs G Sibinga Mulder; Henricus Jm Handgraaf; Danielle J Vugts; Claudia Sewing; Albert D Windhorst; Marieke Stammes; Lioe-Fee de Geus-Oei; Mark W Bordo; J Sven D Mieog; Cornelis Jh van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Am J Nucl Med Mol Imaging Date: 2018-10-20
Authors: Henricus J M Handgraaf; Martin C Boonstra; Hendrica A J M Prevoo; Joeri Kuil; Mark W Bordo; Leonora S F Boogerd; Babs G Sibinga Mulder; Cornelis F M Sier; Maaike L Vinkenburg-van Slooten; A Rob P M Valentijn; Jacobus Burggraaf; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Oncotarget Date: 2017-03-28
Authors: Rohini Sharma; Pablo Oriol Valls; Marianna Inglese; Suraiya Dubash; Michelle Chen; Hani Gabra; Ana Montes; Amarnath Challapalli; Mubarik Arshad; George Tharakan; Ed Chambers; Tom Cole; Jingky P Lozano-Kuehne; Tara D Barwick; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-21 Impact factor: 9.236